Paper3324948
On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics.
Nutt JG. Ann Neurol, 1987. Cited by 171 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. Papers, record 3324948. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3324948
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Levodopa | Major topic |
| Parkinson Disease | Major topic |
| Blood-Brain Barrier | |
| Dose-Response Relationship, Drug | |
| Movement Disorders |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 NS 21062 | NINDS NIH HHS | United States | R01NS021062 | PubMed and NIH |
Source NIH RePORTER
Cited by39
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 171 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,930,793 | Heterogeneous Patterns of Wearing-Off in Parkinson's Disease. | J Pers Med | 2026 | https://conductscience.org/library/papers/42930793 | PubMed |
| 42,181,371 | Controlled Maxillofacial Administration of Levodopa in a Patient With Parkinson's Disease: A First-in-Human 24-Hour Follow-Up Study. | Cureus | 2026 | https://conductscience.org/library/papers/42181371 | PubMed |
| 40,635,563 | Disease-Modifying Trials in Treated Parkinson's Disease: "Stable Treated" Does Not Equate with Biological Stability. | Mov Disord | 2025 | https://conductscience.org/library/papers/40635563 | PubMed |
| 39,500,970 | Non-invasive, continuous oral delivery of solid levodopa-carbidopa for management of Parkinson's disease. | Sci Rep | 2024 | https://conductscience.org/library/papers/39500970 | PubMed |
| 38,863,783 | The mechanisms of white matter injury and immune system crosstalk in promoting the progression of Parkinson's disease: a narrative review. | Front Aging Neurosci | 2024 | https://conductscience.org/library/papers/38863783 | PubMed |
| 36,229,860 | Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease? | Transl Neurodegener | 2022 | https://conductscience.org/library/papers/36229860 | PubMed |
| 30,802,998 | Magnetic resonance imaging-guided phase 1 trial of putaminal AADC gene therapy for Parkinson's disease. | Ann Neurol | 2019 | https://conductscience.org/library/papers/30802998 | PubMed |
| 29,186,917 | The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease. | Molecules | 2017 | https://conductscience.org/library/papers/29186917 | PubMed |
| 26,171,276 | L-Dopa Pharmacokinetic Profile with Effervescent Melevodopa/Carbidopa versus Standard-Release Levodopa/Carbidopa Tablets in Parkinson's Disease: A Randomised Study. | Parkinsons Dis | 2015 | https://conductscience.org/library/papers/26171276 | PubMed |
| 25,112,783 | A randomised clinical trial to evaluate the effects of Plantago ovata husk in Parkinson patients: changes in levodopa pharmacokinetics and biochemical parameters. | BMC Complement Altern Med | 2014 | https://conductscience.org/library/papers/25112783 | PubMed |
| 24,323,838 | Continuous drug delivery in Parkinson's disease. | CNS Drugs | 2014 | https://conductscience.org/library/papers/24323838 | PubMed |
| 22,783,173 | Mathematical insights into the effects of levodopa. | Front Integr Neurosci | 2012 | https://conductscience.org/library/papers/22783173 | PubMed |
| 22,135,765 | Reliability in one-repetition maximum performance in people with Parkinson's disease. | Parkinsons Dis | 2012 | https://conductscience.org/library/papers/22135765 | PubMed |
| 21,936,884 | Validation of 24-hour ambulatory gait assessment in Parkinson's disease with simultaneous video observation. | Biomed Eng Online | 2011 | https://conductscience.org/library/papers/21936884 | PubMed |
| 21,080,186 | Pharmacokinetics of levodopa. | J Neurol | 2010 | https://conductscience.org/library/papers/21080186 | PubMed |
| 17,828,529 | Locomotor response to levodopa in fluctuating Parkinson's disease. | Exp Brain Res | 2008 | https://conductscience.org/library/papers/17828529 | PubMed |
| 16,485,914 | Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update. | Clin Pharmacokinet | 2006 | https://conductscience.org/library/papers/16485914 | PubMed |
| 16,320,098 | Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease. | J Pharmacokinet Pharmacodyn | 2005 | https://conductscience.org/library/papers/16320098 | PubMed |
| 15,502,970 | Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat. | Naunyn Schmiedebergs Arch Pharmacol | 2004 | https://conductscience.org/library/papers/15502970 | PubMed |
| 11,548,910 | Economic and health-related quality of life considerations of new therapies in Parkinson's disease. | Pharmacoeconomics | 2001 | https://conductscience.org/library/papers/11548910 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3324948
GET https://conductscience.org/api/papers/v1/3324948/cited_by?page=2